The website regulation.gov.ru contains a draft government decree that amends the rules for the distribution of subsidies to regions for outpatient drug provision for patients with a high risk of developing cardiovascular diseases (CVD) and complications in Appendix No. 10 of the state program “Health Development”. The document states that citizens after acute cardiovascular events will be able to receive medications for two years, and not for one year, as now.
Since 2020, Russia has been implementing a program to prevent complications after acute cerebrovascular accident, myocardial infarction, coronary artery bypass surgery, coronary angioplasty with stenting and catheter ablation for CVD. Patients who have suffered the listed cardiovascular events receive free medications at the clinic for a year. We are talking about citizens who do not have the right to preferential drug coverage. For the program, by order of the Ministry of Health, a list of drugs from 23 INNs was created.
The regions are allocated 10.15 billion rubles annually from the federal budget for the purchase of these drugs. The program will last until the end of 2023.
As stated in the explanatory note to the document, in 2020 the regions spent 9.97 billion rubles on the purchase of these drugs. (98.2%). At the same time, patients received medicines worth only 5.4 billion rubles. (48.4% of the provided). This may be due to the late start of the program in the regions – April-May 2020, as well as a decrease in the volume and quality of dispensary observation due to the coronavirus pandemic, the Ministry of Health believes.
At the same time, experts expect amendments to the list of 23 INNs that will make it more valuable for patients. Now there are many antiarrhythmics in it, some of them are not suitable for every patient, especially with acute coronary syndrome, the head of the department and clinic of faculty therapy of the Military Medical Academy named after. CM. Kirova, professor Vadim Tyrenko.
“In my opinion, this list should contain innovative drugs, which will become a magnet for patients. For drugs costing less than 100 rubles, a person is unlikely to go to the clinic, wait for a prescription to be issued and then go to the pharmacy,” he explained.
Tyrenko also believes that the list should not include simvastatin, which is no longer used for secondary prevention. “According to the standard, everyone who receives angioplasty should receive a highly effective statin – atorvastatin or rosuvastatin. With simvastatin it is hardly possible to achieve indicative indicators,” the expert noted.